FDA Approval Summary: Atezolizumab plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1

Preeti Narayan, Sakar Wahby, Jennifer J. Gao, Laleh Amiri-Kordestani, Amna Ibrahim, Erik Bloomquist, Shenghui Tang, Yuan Xu, Jiang Liu, Wentao Fu, Pengfei Song, Bellinda L. King-Kallimanis, Sherry Hou, Yutao Gong, Shyam Kalavar, Soma Ghosh, Reena Philip, Kirsten B. Goldberg, Marc R. Theoret, Gideon M. BlumenthalPaul G. Kluetz, Rajeshwari Sridhara, Richard Pazdur, Julia A. Beaver

Research output: Contribution to journalArticle

Fingerprint Dive into the research topics of 'FDA Approval Summary: Atezolizumab plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1'. Together they form a unique fingerprint.

Medicine & Life Sciences